Chief Scientific Officer · Founder, Aravax
| Role | Organisation | Sources |
|---|---|---|
| Chief Scientific Officer · Founder | Aravax | Brandon BioCatalyst, Breakthrough Victoria |
| Postdoctoral Researcher (former) | WEHI | Brandon BioCatalyst |
Stories naming Dr Sara Prickett. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile tracing Sara Prickett's path from UK labs to co-founding Aravax, the peanut-allergy biotech Brandon Capital backed, as its Phase II trial nears readout in mid-2026.
Breakthrough Victoria announces a $12 million investment in Aravax, part of a $66 million Series B, advancing the biotech's peanut allergy immunotherapy into phase two trials in Australia and the United States.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·Business News Australia·@AuManufacturing·Forbes Australia·Startup News (WA)